Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Dopamine agonists may be useful in depression associated (or not) with PD and pramipexole has been demonstrated to have the same efficacy of selective serotonin-reuptake inhibitors (SSRIs).

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

Tavapadon hit the primary endpoint in one phase 3 trial in April, before AbbVie closed the takeover, and racked up another victory in September. AbbVie completed the set Monday by reporting data from ...